ArticleAnnals of surgical oncology2026
Discordance between Breast and Axillary Responses After Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: Implications for Surgical De-Escalation.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeOur objective was to investigate breast-axillary pathological response discordance after neoadjuvant chemotherapy (NACT) in triple-negative breast cancer (TNBC).
methodsWe retrospectively analyzed 651 patients with TNBC who received NACT followed by surgery. Four composite response patterns were defined by breast pathological complete response (BpCR) and nodal pathological complete response (NpCR). Logistic regression assessed factors associated with residual axillary disease in patients with BpCR and with NpCR in patients without BpCR. Era-stratified analyses compared 2014-2019 and 2020-2024.
resultsDiscordance occurred in 30.6% (199/651). Among patients with BpCR, 17.8% had residual axillary disease. Higher initial clinical nodal (cN) stage was associated with residual axillary disease (all P < 0.05), whereas immunotherapy was associated with lower odds (odds ratio [OR] 0.259; 95% confidence interval [CI] 0.080-0.842; P = 0.025). Human epidermal growth factor receptor 2 (HER2)-low status showed a marginal association (OR 2.599; 95% CI 1.013-6.668; P = 0.047). Era-stratified analyses supported the cN-stage association; immunotherapy was not reliably estimable in 2014-2019 and was favorable but non-significant in 2020-2024. Among patients without BpCR, 34.8% experienced NpCR; initial cN stage was the only independent factor associated with NpCR (all P < 0.001), with an NpCR rate of 80.9% in cN0 disease.
conclusionsBreast-axillary discordance is common after NACT in TNBC. Initial axillary burden was the most consistent factor associated with axillary response. HER2-low may be an exploratory marker, whereas the immunotherapy association requires cautious interpretation. These findings may inform future axillary de-escalation trials.
Indexed as
Identifiers
42624979What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.